You are here: Industry Insights > disease

News List

Otonomy’s renaissance starts as Ménière’s disease drug clears trial fiercebiotech
November 10, 2017
Just weeks after a phase 3 setback caused it to slash staff and R&D programs, Otonomy has bounced back with a positive late-stage trial for its lead candidate Otividex in Ménière’s disease.
US clears first therapy for Batten disease pharmatimes
May 02, 2017
US regulators have approved BioMarin Pharmaceutical’s Brineura as the first treatment for a rare inherited form of Batten disease.
NICE backs new option for Crohn’s disease pharmatimes
May 02, 2017
The National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult...
BioMarin’s Brineura receives positive opinion from CHMP to treat CLN2 disease pharmaceutical-technology
April 25, 2017
BioMarin Pharmaceutical has announced that European Medicines Agency’s (EMA) Committee for Medicinal Products...
Breakthrough multiple sclerosis research sheds light on cause of the disease pharmafile
April 25, 2017
Researchers from the Universities of Exeter and Alberta have identified a protein in the brain which they believe could be key in the onset of multiple sclerosis.
Zambon launches Xadago in Portugal to treat Parkinson’s disease pharmaceutical-technology
April 12, 2017
Italian pharmaceutical company Zambon and its partner Newron Pharmaceuticals have launched Xadago (safinamide) in ...
AbbVie/Janssen’s Imbruvica filed for graft-versus-host-disease pharmatimes
April 07, 2017
US regulators have agreed to review AbbVie and Janssen’s Imbruvica for previously treated chronic ...
US FDA approves Xadago to treat patients with Parkinson’s disease pharmaceutical-technology
March 23, 2017
The US Food and Drug Administration (FDA) has approved Newron Pharmaceuticals’ Xadago (safinamide) tablets to ...
Circassia to acquire US rights to Tudorza and Duaklir from AstraZeneca for $230m pharmaceutical-technology
March 21, 2017
UK-based specialty biopharmaceutical company Circassia Pharmaceuticals has reached an agreement for the transformational acquisition of US commercial rights to two chronic obstructive pulmonary disease (COPD) products from AstraZeneca for a maximum total
Rare disease patients in UK wait average of two years for medications pharmaceutical-technology
March 16, 2017
A new report published by Irish biotechnology company Shire has shown that rare disease patients in England...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page